International Journal of Biomedicine. 2023;13(2):202-204.
Originally published June 5, 2023
Human papillomavirus (HPV) in the genital region is a frequently occurring sexually transmitted disease that can result in genital warts and various types of cancer. Most sexually active individuals acquire HPV at a certain point during their lifetime, but fortunately, several of the most harmful HPV types are preventable with vaccinations. All boys and girls aged 9 to 12 should get the HPV vaccine, although it can be given to individuals up to age 45. The HPV vaccine triggers an immune response that helps the body recognize and fight off the virus. There are currently two different HPV vaccines available: Gardasil and Cervarix. Gardasil guards against the two HPV strains that most commonly result in cervical cancer (CC) and various additional strains that can result in genital warts or other types of cancer. Cervarix only offers protection against the two forms of HPV that trigger CC. Mild side effects may occur, but more severe side effects are rare. Despite the availability of HPV vaccination, vaccination rates remain suboptimal in many countries. Raising awareness and expanding access to HPV vaccination are critical steps toward reducing HPV-related diseases. This article explores the basics of HPV and the role of vaccination in preventing its spread.
1. Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016 Feb;13(2):119-32. doi: 10.1038/nrclinonc.2015.146.
2. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA. 2007 Feb 28;297(8):813-9. doi: 10.1001/jama.297.8.813.
3. Stanley M. HPV Vaccines: Impact of Current Vaccines and Effect of New Vaccines in the Pipeline. Gynecologic Oncology. 2012;124(3):S1-S10. doi: 10.1016/j.ygyno.2012.01.035
4. Drolet M, Bénard É, Pérez N, Brisson M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019 Aug 10;394(10197):497-509. doi: 10.1016/S0140-6736(19)30298-3.
5. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016 Aug 15;63(4):519-27. doi: 10.1093/cid/ciw354.
6. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al.; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 19;372(8):711-23. doi: 10.1056/NEJMoa1405044.
7. Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013 Oct;445(1-2):224-31. doi: 10.1016/j.virol.2013.07.015.
8. Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005 Mar;32 Suppl 1:S7-15. doi: 10.1016/j.jcv.2004.12.006.
9. Stanley MA. Immunobiology of papillomavirus infections. J Clin Virol. 2010; 48(Supplement 1), S1-S2.
10. Campo MS. Animal models of papillomavirus pathogenesis. Virus Res. 2002 Nov;89(2):249-61. doi: 10.1016/s0168-1702(02)00193-4.
11. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010 May;117(2 Suppl):S5-10. doi: 10.1016/j.ygyno.2010.01.024.
12. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA Jr, Unger ER; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30. Erratum in: MMWR Recomm Rep. 2014 Dec 12;63(49):1182.
13. Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014 Jul;2(7):e406-14. doi: 10.1016/S2214-109X(14)70237-2.
14. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013 Dec 20;31(36):4550-9. doi: 10.1200/JCO.2013.50.3870.
15. Chelimo C, Wouldes TA, Cameron LD, Elwood JM, Kavanagh K. HPV prevalence and type-distribution in cervical and vaginal cancer specimens from women in Nairobi, Kenya. Infectious Agents and Cancer. 2018;13(1):23. doi: 10.1186/s13027-018-0197-3
16. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009 Feb 20;384(2):260-5. doi: 10.1016/j.virol.2008.11.046.
17. Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009 May;20(4):449-57. doi: 10.1007/s10552-008-9276-9.
18. Harper DM, Nieminen P, Paavonen J, Lehtinen M, Jaisamrarn U. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine. 32-year follow-up of a randomized clinical trial. JAMA Netw Open. 2019;2(2):e187883. doi: 10.1001/jamanetworkopen.2018.7883
19. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
20. Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA. 2014 Feb 12;311(6):597-603. doi: 10.1001/jama.2014.95.
Received March 20, 2023.
Accepted April 25, 2023.
©2023 International Medical Research and Development Corporation.